

Industry Experience

Pharmaceutical

Healthcare

Research Science

Media

Higher Education

Consulting

Functional Experience

Scientific Communications

Scientific Marketing

Patient Education

Content Creation

Website Content

Medical Publications

Manuscripts

Technical Brochures

Fact Sheets

Slide Decks

Scientific Posters

Clinical Data

Clinical Trial Summaries

Mathematical Modeling

Strategic Planning

Training

Education & Certifications

Duke University

Ph.D., Biomedical Engineering

Cornell University

Master of Engineering

Cornell University

B.S. Biological Engineering

Contact Information

Office: 919.651.0085

michelle@orchardpointgroup.com

Katherine A. DeBruin, Ph.D.

Selected Accomplishments

- Highly published scientific communications and scientific marketing expert backed up by over ten years of research and content creation for Fortune Global 500 companies such as GlaxoSmithKline and other large pharmaceutical firms like Baxter, Genentech and Wyeth/Pfizer.
- As Senior Manager in US HIV Marketing at GlaxoSmithKline, created and led *APositiveLife*, the HIV division's patient education and outreach initiative, encompassing strategic planning, unification of numerous internal stakeholders, and design and execution of a comprehensive patient education curriculum in print, slide and interactive media.
- As a Scientific Communications Manager for GlaxoSmithKline: Linked scientific/clinical data to commercial messages and positioning by creating content for advisory boards and speaker training meetings in the US, as well as integrating with European and global counterparts.
- Trained as a scientist, with hands-on experience designing electrodes for medical devices using mathematical modeling.
- Expertise in developing and writing medical manuscripts, including the results of clinical trials, for publication in peer-reviewed journals.

Writing and authoring examples include:

- Fischl MA, Burnside AF Jr., Farthing CF, et al. Twice-daily Trizivir versus Combivir/abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. *Pharmacotherapy* 2003;23:1432-1440.
- Sension MG, Bellos NC, Johnson J, et al. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients. *HIV Clinical Trials* 2002;3:361-370.
- Elion R, Berger D, Richmond G, et al. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. *HIV Clinical Trials*, in press.
- All on-label slide decks for Combivir®, Epivir®, Epzicom®, Lexiva®, Trizivir®, and Ziagen®, 2004-2006
- Brochures describing cytomegalovirus (CMV) and hepatitis C, 2010
- Rewrote content for WebAssign.com, a provider of online instructional tools for faculty and students, 2009
- Edited all content for APositiveLife.com, a 100+ page comprehensive unbranded patient website, 2007-2008
- Updated and edited all content for TreatHIV.com, Epzicom.com, and Trizivir.com, 2007-2008
- DeBruin KA and Krassowska W. Modeling electroporation in a single cell: I. Effects of field strength and rest potential. *Biophysical Journal* 1999; 77:1213-1224.
- DeBruin KA and Krassowska W. Modeling electroporation in a single cell: II. Effects of ionic concentrations. *Biophysical Journal* 1999;77:1225- 1233.
- DeBruin KA and Krassowska W. Electroporation and shock-induced transmembrane potential in a cardiac fiber during defibrillation strength shocks. *Annals of Biomedical Engineering* 1998;26:584-596.